ideasIdea
Sponsors deposit the confirmatory trial budget in escrow at accelerated approval
To get an early approval, a company would set aside the money for the follow-up trial up front, so the trial cannot be quietly abandoned.
Confirmatory trials for accelerated approvals are often delayed or redesigned in ways that reduce their chance of a clear answer. The proposal is a financial escrow: at approval the sponsor deposits the estimated cost of the pre-agreed confirmatory trial with an independent trustee. The funds are released against enrolment and reporting milestones; if the sponsor defaults, the trustee funds an academic cooperative group to complete the trial. This complements, rather than replaces, an automatic sunset.
Hypothesis
Escrow-backed confirmatory trials reach their primary readout a median of 18 months sooner than historical confirmatory trials, and the proportion never reported falls to near zero.
Rationale
Escrow converts a soft regulatory commitment into a hard financial one and creates a funded route for independent completion when commercial interest wanes (for example after a competing product launches). Environmental remediation bonds work on the same logic.
What would test it
Legislative pilot in one region for new accelerated oncology approvals; compare time to confirmatory readout with concurrent non-escrow approvals elsewhere.
Maturity
speculative
Who has to act
policy
Cost to try
Small (under $1M)
Years to first evidence
6
Bottlenecks it attacks
- Regulatory divergence between regions · Regulatory divergence means a drug approved in one country can take years to reach another, or never arrive.
- Incentives reward me-too drugs and marginal gains · The system pays the same for a drug that adds two months as for a cure, so companies race to copy rather than to cure.